I am going to repost these words by Lefevre from 30 June as a...

I am going to repost these words by Lefevre from 30 June as a reminder of this company's short to medium term focus:

"I believe that Genova has 15000 clinicians. I remember Luke mentioning in a podcast that he is expecting at least 1 Microba kit sale per month per clinician which at A$90 per kit is $1,350,000 per month.

Geneva expects big things which is why they have invested in their own lab. They will promote to their 15000 clinicians and expect results. Once the lab is done with their work the data is sent to Microba in Brisbane for the IP protected algo to do its thing. It's about 90% profit margin to Microba.

It will probably take 6 months or so for Geneva to start reaching targets.

It's a brilliant model. Huge growth ahead.

I expect in years time we will be on a $20 mil plus run rate."

Luke Reid, their CEO, has said that a feature that makes Microba very different from its seeming peers that are all working through the clinical studies process is that Microba is not years away from revenue like the rest of them are. Microba already gets revenue from its kits and if the figures that Lefevre used are even close to the mark then by the end of this fiscal year its revenue will be multiples of what it is now. Definitely something to work with there imo.